Covid-flu joint booster jab possible late 2023: Moderna
Skip to main content
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Splash
  • Features
  • Videos
  • Long Read
  • Games
  • Epaper
  • More
    • COVID-19
    • Bangladesh
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Subscribe
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
The Business Standard
THURSDAY, MAY 19, 2022
THURSDAY, MAY 19, 2022
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Splash
  • Features
  • Videos
  • Long Read
  • Games
  • Epaper
  • More
    • COVID-19
    • Bangladesh
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Subscribe
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
Covid-flu joint booster jab possible late 2023: Moderna

Coronavirus chronicle

BSS/AFP
18 January, 2022, 09:45 am
Last modified: 18 January, 2022, 09:50 am

Related News

  • China Junshi's potential Covid drug shows promise in small trial
  • Indonesia to drop outdoor mask mandate as Covid-19 infections drop
  • N Korean leader slams officials' 'immaturity' in response to Covid outbreak
  • Shanghai achieves 'zero Covid' status but normal life is weeks away
  • N Korea mobilises army, steps up tracing amid Covid wave

Covid-flu joint booster jab possible late 2023: Moderna

 Moderna's experimental flu shot, targeting four major strains, is based on the same mRNA method used in its Covid-19 jabs

BSS/AFP
18 January, 2022, 09:45 am
Last modified: 18 January, 2022, 09:50 am
Moderna has recently signed vaccine orders for 2022 worth $17 billion — which would make it one of the best-selling drugs in the world. Photo: Reuters
Moderna has recently signed vaccine orders for 2022 worth $17 billion — which would make it one of the best-selling drugs in the world. Photo: Reuters

Moderna aims to roll out a combined Covid-flu-RSV booster vaccine in late 2023, the US pharmaceutical firm said Monday, hoping a joint jab would encourage people to get an annual shot.

The single vaccine for Covid-19, influenza and respiratory syncytial virus -- a common virus that causes the cold, but can be more serious for infants and elderly people -- could appear on the market before 2024.

"Best-case scenario will be the fall of '23," Moderna chief executive Stephane Bancel told a virtual World Economic Forum roundtable session.

"I don't think it would happen in every country, but we believe it's possible to happen in some countries next year.

"Our goal is to be able to have a single annual booster so that we don't have compliance issues where people don't want to get two to three shots a winter, but to get one dose."

 - Trials in progress -

 Bancel said the RSV programme was in Phase III trials -- the final stage of human testing -- while the flu programme should be entering Phase III in the second quarter of this year.

 Moderna's experimental flu shot, targeting four major strains, is based on the same mRNA method used in its Covid-19 jabs.

The technology provokes an immune response by delivering genetic molecules containing the code for key parts of a pathogen into human cells.

While Moderna's Covid-19 vaccine was based on the original strain of the virus, it was working on finishing an Omicron-specific jab within weeks, ahead of trials, said Bancel.

"We're hoping in the March timeframe we should be able to have data to share with regulators to figure out the next step forward."

- Hunt for 'holy grail' -

Beyond a vaccine specific to Omicron -- which is rapidly becoming the world's dominant strain -- laboratories are also pursuing a vaccine that works against all current and future Covid-19 mutations.

"There's some private sector partners that are pursuing it," said Richard Hatchett, chief executive of the Coalition for Epidemic Preparedness Innovations, which funds vaccine research and development.

"That would be the holy grail because we really don't want to be in position where we're chasing the new variants that are going to come.

"We don't want to be in a position where we're having to vaccinate everybody in the world every three or six months, or even annually, ideally."

Top US pandemic advisor Anthony Fauci added: "We really don't want to get into the whack-a-mole approach towards every new variant... because you'd be chasing it forever."

 Bancel meanwhile said that Moderna had shipped 807 million doses of Covid-19 vaccine in 2021, of which a quarter went to middle- and low-income countries.

Thanks to extra capacity coming on stream before the end of March, the company hopes to be able to make two to three billion doses this year.

Top News / World+Biz

Moderna / booster / Covid / Flu

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Nearly 58% hike in bulk power price on cards
    Nearly 58% hike in bulk power price on cards
  • Illustration: TBS
    Let taka slide
  • Inflation jumps to 6.29% in April
    Inflation jumps to 6.29% in April

MOST VIEWED

  • Representational image.
    China Junshi's potential Covid drug shows promise in small trial
  • A woman wearing protective mask walks at a sidewalk near business district in Jakarta, Indonesia March 2, 2020. REUTERS/Willy Kurniawan/Files
    Indonesia to drop outdoor mask mandate as Covid-19 infections drop
  • North Korean leader Kim Jong Un presides over a politburo meeting of the ruling Workers' Party, amid the coronavirus disease (COVID-19) pandemic, May 17, 2022, in this photo released May 18, 2022 by North Korea's Korean Central News Agency (KCNA). KCNA via REUTERS
    N Korean leader slams officials' 'immaturity' in response to Covid outbreak
  • North Korea Covid outbreak is 'worrying' for new variants -WHO
    North Korea Covid outbreak is 'worrying' for new variants -WHO
  • People watch a TV broadcasting a news report on the coronavirus disease (Covid-19) outbreak in North Korea, at a railway station in Seoul, South Korea on 17 May 2022. Photo: Reuters.
    N Korea Covid outbreak could have 'devastating' impact on human rights, UN says
  • Two women hug at a closed street during lockdown, amid the coronavirus disease (COVID-19) pandemic, in Shanghai, China, May 16, 2022. REUTERS/Aly Song
    Shanghai achieves 'zero Covid' status but normal life is weeks away

Related News

  • China Junshi's potential Covid drug shows promise in small trial
  • Indonesia to drop outdoor mask mandate as Covid-19 infections drop
  • N Korean leader slams officials' 'immaturity' in response to Covid outbreak
  • Shanghai achieves 'zero Covid' status but normal life is weeks away
  • N Korea mobilises army, steps up tracing amid Covid wave

Features

‘The geopolitical landscape is undergoing profound change, Dhaka needs to craft proactive strategies’

‘The geopolitical landscape is undergoing profound change, Dhaka needs to craft proactive strategies’

21h | Interviews
Graphics: TBS

Facebook and Bangladeshi politicians: A new tide in mass political communication?

22h | Panorama
Despite Bangladesh having about 24,000 km of waterways, only a few hundred kilometres are covered by commercial launch services. Photo: Saad Abdullah

Utilising waterways: When common home-goers show the way

1d | Panorama
Illustration: TBS

How Putin revived Nato

1d | Panorama

More Videos from TBS

Cannes Film Festival 2022 resumes after 2 years

Cannes Film Festival 2022 resumes after 2 years

10h | Videos
Pension is coming for all

Pension is coming for all

10h | Videos
Bakery business in crisis for increased raw material prices

Bakery business in crisis for increased raw material prices

12h | Videos
Foods that have the most protein

Foods that have the most protein

12h | Videos

Most Read

1
Representative Photo: Pixabay.
Bangladesh

Microplastics found in 5 local sugar brands

2
Mushfiq Mobarak. Photo: Noor-A-Alam
Panorama

Meet the Yale professor who anchors his research in Bangladesh and scales up interventions globally

3
The story of Bangladesh becoming a major bicycle exporter
Industry

The story of Bangladesh becoming a major bicycle exporter

4
How Bangladesh can achieve edible oil self-sufficiency with local alternatives
Bazaar

How Bangladesh can achieve edible oil self-sufficiency with local alternatives

5
Govt tightens belt to relieve reserve
Economy

Govt tightens belt to relieve reserve

6
PK Halder: How a scamster rose from humble beginnings to a Tk11,000cr empire
Crime

PK Halder: How a scamster rose from humble beginnings to a Tk11,000cr empire

The Business Standard
Top
  • Home
  • Entertainment
  • Sports
  • About Us
  • Bangladesh
  • International
  • Privacy Policy
  • Comment Policy
  • Contact Us
  • Economy
  • Sitemap
  • RSS

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net

Copyright © 2022 THE BUSINESS STANDARD All rights reserved. Technical Partner: RSI Lab